Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results In Western And Asian Patients In Updated Analysis From Global Phase III HARMoni Study

July 22 (Reuters) - Summit Therapeutics Inc (SMMT.O) said ivonescimab plus chemotherapy showed consistent, favorable overall survival results in Western and Asian patients in an updated analysis from the global phase III HARMoni study.

• Ivonescimab plus chemotherapy showed a positive overall survival trend in Asian and Western patients.
• The phase III HARMoni study showed a statistically significant progression-free survival benefit.
• Ivonescimab continued to show an acceptable safety profile, with no new safety signals.
• The FDA accepted the BLA for ivonescimab, with a PDUFA date of November 14, 2026.